Affordable Access

deepdyve-link
Publisher Website

Self-blinding citizen science to explore psychedelic microdosing.

Authors
  • Szigeti, Balázs1
  • Kartner, Laura1
  • Blemings, Allan1
  • Rosas, Fernando1, 2, 3
  • Feilding, Amanda4
  • Nutt, David J1, 5
  • Carhart-Harris, Robin L1
  • Erritzoe, David1, 5
  • 1 Centre for Psychedelic Research, Imperial College London, London, United Kingdom. , (United Kingdom)
  • 2 Data Science Institute, Imperial College London, London, United Kingdom. , (United Kingdom)
  • 3 Center for Complexity Science, Imperial College London, London, United Kingdom. , (United Kingdom)
  • 4 Beckley Foundation, Oxford, United Kingdom. , (United Kingdom)
  • 5 Centre for Psychiatry, Imperial College London, London, United Kingdom. , (United Kingdom)
Type
Published Article
Journal
eLife
Publisher
"eLife Sciences Organisation, Ltd."
Publication Date
Mar 02, 2021
Volume
10
Identifiers
DOI: 10.7554/eLife.62878
PMID: 33648632
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Psychedelic psychotherapy, therapy enhanced with psychedelic drugs such as LSD or psilocybin (the active ingredient of ‘magic mushrooms’), has been suggested to improve psychological well-being. For this reason, trials on psychedelic therapy for the treatment of depression, addiction and other conditions are ongoing. Recently, ‘microdosing’ – a way of administering psychedelics that involves taking about 10% of a recreational dose two or three times per week – has gained popularity. Unlike taking large doses of psychedelics, microdosing does not induce hallucinations, but anecdotal reports suggest that it yields similar benefits as psychedelic therapy. A key feature of modern medicine are ‘placebo control’ studies that compare two groups of patients: one that takes a drug and another that takes inactive pills, known as placebos. Crucially, neither group knows whether they are taking drug or placebo. This control ensures that observed effects are due to the drug itself and not to unrelated psychological causes. For example, in trials of mood medicines, participants often expect to feel happier, which in itself improves their mood even when taking a placebo. This is known as the placebo effect. Restrictive drug policies make placebo-controlled studies on psychedelics difficult and expensive, in particular for microdosing, which involves taking psychedelics over a longer time period. To overcome this problem, Szigeti et al. developed a new citizen-science approach, where microdosers implemented their own placebo control based on online instructions. The advantages are the low cost and the ability to recruit participants globally. The experiment was completed by 191 microdosers, making it the largest placebo-controlled study on psychedelics to-date, for a fraction of the cost of an equivalent clinical study. The trial examined whether psychedelic microdosing can improve cognitive function and psychological well-being. The team found that microdosing significantly increased a number of psychological measures, such as well-being and life satisfaction. However, participants taking placebo also improved: there were no significant differences between the two groups. The findings confirmed positive anecdotes about microdosing improving people’s moods, but at the same time show that taking empty capsules, knowing they might be microdoses, have the same benefits. This result suggests that the observed benefits are not caused by the microdose, but rather by psychological expectations. The study’s innovative ‘do-it-yourself’ approach to placebo control may serve as a template for future citizen science studies on other popular phenomena where positive expectations and social factors could play a role, such as cannabidiol (CBD) oils, nootropics and nutrition.

Report this publication

Statistics

Seen <100 times